- Trial phase
- Phase 2
- Time to market
- Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
- Why 4/10
- The Phase 2 topline readout (the most recent binary catalyst) occurred on August 10, 2026, and the next hard dated catalyst is the planned Phase 3 initiation in 2027, which is not a binary regulatory or pivotal readout. With no PDUFA or pivotal topline readout scheduled within the next ~12 months, the impact score is capped at 4.
The next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.
Price Chart
Executive Summary
ABCL635 is AbCellera Biologics' lead wholly-owned pipeline asset, a monoclonal antibody targeting NK3R for non-hormonal treatment of moderate-to-severe hot flashes (vasomotor symptoms) due to menopause. In August 2026, the company reported positive Phase 2 topline data showing an 83% reduction in hot flash frequency versus 33% on placebo after a single dose, which the company calls best-in-class. The stock surged ~100% on the news, and the company raised $200M in an oversubscribed offering to fund development. AbCellera plans to advance ABCL635 into Phase 3 in 2027. The drug faces established oral competitors (Astellas' Veozah and Bayer's Lynkuet) but differentiates with monthly injectable dosing. Analyst consensus is strongly bullish with a mean price target of $17.17, representing ~37% upside from the current $12.50.
How It Works
ABCL635 is a monoclonal antibody that blocks the neurokinin 3 receptor (NK3R), a protein involved in the brain's temperature regulation center. By blocking NK3R, the drug aims to reduce the frequency and severity of hot flashes (vasomotor symptoms) in menopausal women without using hormones. It is designed as a long-acting injectable, potentially requiring only monthly dosing.
Trial Status
Phase 2 portion of a Phase 1/2 trial (NCT07118891) has completed enrollment (136 patients) and reported positive topline results on August 10, 2026. The trial is active but not recruiting, with estimated primary completion in February 2027. Phase 3 is planned to start in 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 trial initiation in 2027 (no specific date announced)
- Potential data presentations at medical conferences (TMS 2026 Annual Meeting presentation already scheduled for October 2026)
- FDA feedback on Phase 3 trial design
- Any potential partnership or licensing deal for ABCL635
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbCellera Biologics Inc. 8-K ABCL ·Originating report